CA-125 is an antigenic determinant of a murine immunoglobulin Ig1 monoclonal antibody that was raised against an epithelial ovarian carcinoma cell line and is expressed in more than 80% of nonmucinous epithelial ovarian cancers.
CA-125Â (also known as mucin 16 or MUC16) is a glycoprotein.Â CA-125Â in humans is encoded by theÂ MUC16Â gene.Â CA-125Â is used as a tumor marker becauseÂ CA-125Â concentrations may be elevated in the blood of some patients with ovarian cancer, but also in some benign conditions.Â CA-125Â levels in serum are elevated in approximately 50 percent of women with the early stage the disease, and in over 80 percent of women with advanced ovarian cancer.
MonitoringÂ CA-125serum levels is also useful for determining the response of a patient to ovarian cancer therapy as well as for predicting a patientâ€™s prognosis after treatment. In general, persistence of high levels ofÂ CA-125Â during therapy is associated with poor survival rates in patients.
Also, an increase inÂ CA-125Â levels in a patient during remission is a strong predictor of recurrence of ovarian cancer. The specificity ofÂ CA-125Â is limitedÂ becauseÂ CA-125Â levels are elevated in approximately 1% of healthy women and fluctuate during the menstrual cycle.Â CA-125Â is also increased in a variety of benign and malignant conditions
- Dasgupta A, et al. “Learn More about CA-125.” Science Direct(n.d.): n. pag. Elsevier. Web.